Business context and reporting period
Prestige Consumer Healthcare Inc. filed this unaudited Form 10-Q for the three months ended June 30, 2023, the first quarter of fiscal 2024. The company develops, manufactures, markets and distributes over-the-counter healthcare products in North America and certain international markets. Comparative figures are for the three months ended June 30, 2022.
Key financial metrics
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Total revenue | $279.3 million | $277.1 million | Up $2.3 million (0.8%) |
| Gross profit / margin | $154.7 million / 55.4% | $160.1 million / 57.8% | Down $5.4 million; margin down 2.4 percentage points |
| Operating income | $85.2 million | $87.0 million | Down $1.8 million |
| Net income | $53.3 million | $55.3 million | Down $2.0 million |
| Diluted EPS | $1.06 | $1.09 | Down $0.03 |
| Operating cash flow | $48.1 million | $58.2 million | Down $10.2 million |
| Cash and cash equivalents | $54.6 million | $58.5 million at March 31, 2023 | Down $3.9 million |
Interest expense, net rose to $17.7 million from $15.3 million, despite lower average debt, as average borrowing costs increased to 5.3% from 4.1%. The effective tax rate was 22.5%, versus 22.0%.
Debt, liquidity and capital allocation
Debt totaled $1.33 billion before unamortized debt costs ($1.317 billion net) at June 30, 2023, consisting of $1.0 billion of senior notes and $330 million of term loans. The company had no borrowings outstanding under its asset-based revolver and reported $174.9 million of available borrowing capacity. It repaid $30 million of term loans during the quarter. Management said operating cash and existing credit facilities should fund working capital and capital expenditures for the next 12 months, excluding acquisitions. The company was in compliance with its debt covenants and expected to remain compliant over the next 12 months.
Financing activities used $54.2 million, including $25.0 million of share repurchases and $30.0 million of term-loan repayments. The board authorized a $25.0 million repurchase program in May, completed during the quarter. No common-stock dividends had been declared or paid.
Material changes and management commentary
- North American OTC revenue increased 1.5% to $246.1 million; International OTC revenue declined 4.0% to $33.2 million. North American growth was led by dermatological and gastrointestinal products, partly offset by women’s health. International declines were mainly in gastrointestinal and eye and ear care.
- Gross margin fell primarily because of higher supply-chain costs and product mix; pricing actions partly offset the decline in North America. International gross margin was pressured mainly by product mix.
- Operating cash flow decreased primarily due to increased working capital. Inventory rose to $169.8 million from $162.1 million at March 31, 2023.
- General and administrative expense increased to $27.7 million from $26.7 million, mainly due to compensation costs. Depreciation and amortization expense decreased to $5.6 million from $6.4 million, primarily because of lower amortization following fiscal 2023 impairment charges.
Outlook, risks and unusual items
The filing provides no specific revenue, earnings or other quantitative guidance. Management described economic conditions as volatile and uncertain, citing inflation, higher interest rates, geopolitical events, supply constraints and changing shopping patterns. The company reported no material adverse effect from these conditions to date, but warned that supply, labor or input-cost disruptions could materially affect operations, liquidity and results.
Risks include customer and channel concentration (Walmart represented 20.8% of gross revenue and Amazon 11.0% in the quarter), reliance on third-party manufacturers and logistics providers, and the company’s substantial goodwill and intangible assets. The company recorded $48.8 million of goodwill impairment and $321.4 million of intangible-asset impairment in fiscal 2023; it reported no indicators of impairment at June 30, 2023. Routine legal matters were not expected to have a material adverse effect. Approximately $330 million of debt carried variable rates; a 1 percentage-point rate increase was estimated to raise quarterly pre-tax expense and cash outflow by about $0.9 million. The company completed its transition of discontinued reference rates to SOFR effective July 1, 2023.
Important facts for investors to verify
- Whether gross-margin pressure from supply costs and product mix eases, and whether pricing offsets input-cost inflation.
- Whether International OTC sales and contribution margins stabilize after quarter-over-quarter declines versus the prior-year quarter.
- Working-capital trends and operating cash generation, including inventory levels and cash conversion.
- Debt-service capacity, variable-rate exposure, covenant compliance and availability under the revolving facility.
- Customer, manufacturer and distribution concentration, and whether any impairment indicators emerge for goodwill or intangible assets.